January 2010 Volume 7 Number 1
Visit Nature Reviews Cardiology online to browse the journal.
Now available at
http://links.ealert.nature.com/ctt?kn=38&m=34505386&r=MTc2NDI1MzEzNAS2&b=2&j=NjI4MDYxMzgS1&mt=1&rt=0
Please note that you need to be a subscriber to enjoy full text access
to Nature Reviews Cardiology online. To purchase a subscription,
please visit:
http://links.ealert.nature.com/ctt?kn=41&m=34505386&r=MTc2NDI1MzEzNAS2&b=2&j=NjI4MDYxMzgS1&mt=1&rt=0
Alternatively, to recommend a subscription to your library, please visit
http://links.ealert.nature.com/ctt?kn=70&m=34505386&r=MTc2NDI1MzEzNAS2&b=2&j=NjI4MDYxMzgS1&mt=1&rt=0
*********************************************************************
Nature Reviews Cardiology Impact Factor: 5.972*
(*Journal Citation Reports, Thomson, 2008)
*********************************************************************
=========================== ADVERTISEMENT ===========================
Keep your patients informed and help them be prepared with specially
designed, easy-to-read documents explaining specific diagnostic tests
for the evaluation of heart failure. Available to download and print.
Click to learn more.
http://links.ealert.nature.com/ctt?kn=61&m=34505386&r=MTc2NDI1MzEzNAS2&b=2&j=NjI4MDYxMzgS1&mt=1&rt=0
=====================================================================
=========================== ADVERTISEMENT ===========================
Review Series: New to Hypertension Research
In 2010 Hypertension Research will publish Review Series articles.
Bringing together related research from around the world the Review
Series will be your outlet for some of the latest information in
hypertension and related cardiovascular diseases.
The 2010 Review Series topics include:
* (Pro)Renin Receptors
* Diurnal Variation in Blood Pressure
* Clinical Implication and Pathogenesis
* Salt Intake and Inflammation in Hypertension
Take advantage of the Hypertension Research Review Series today!
http://links.ealert.nature.com/ctt?kn=64&m=34505386&r=MTc2NDI1MzEzNAS2&b=2&j=NjI4MDYxMzgS1&mt=1&rt=0
=====================================================================
----------------------
RESEARCH HIGHLIGHTS
----------------------
Acute coronary syndromes: Preventing sudden cardiac death early after
myocardial infarction-ICDs are not the solution
p1 | doi:10.1038/nrcardio.2009.211
http://links.ealert.nature.com/ctt?kn=3&m=34505386&r=MTc2NDI1MzEzNAS2&b=2&j=NjI4MDYxMzgS1&mt=1&rt=0
Heart failure: Targeting collagen metabolism in preserved systolic
function HF
p2 | doi:10.1038/nrcardio.2009.213
http://links.ealert.nature.com/ctt?kn=6&m=34505386&r=MTc2NDI1MzEzNAS2&b=2&j=NjI4MDYxMzgS1&mt=1&rt=0
DESs in ULMCA disease
p2 | doi:10.1038/nrcardio.2009.215
http://links.ealert.nature.com/ctt?kn=15&m=34505386&r=MTc2NDI1MzEzNAS2&b=2&j=NjI4MDYxMzgS1&mt=1&rt=0
Atrial fibrillation: Medical therapy reduces arrhythmia recurrence early
after AF ablation
p3 | doi:10.1038/nrcardio.2009.212
http://links.ealert.nature.com/ctt?kn=20&m=34505386&r=MTc2NDI1MzEzNAS2&b=2&j=NjI4MDYxMzgS1&mt=1&rt=0
Diabetes: Unraveling the DCM phenotype
p3 | doi:10.1038/nrcardio.2009.214
http://links.ealert.nature.com/ctt?kn=10&m=34505386&r=MTc2NDI1MzEzNAS2&b=2&j=NjI4MDYxMzgS1&mt=1&rt=0
Bleeding predicts ischemia in PAD
p3 | doi:10.1038/nrcardio.2009.216
http://links.ealert.nature.com/ctt?kn=14&m=34505386&r=MTc2NDI1MzEzNAS2&b=2&j=NjI4MDYxMzgS1&mt=1&rt=0
Coronary artery disease: Long-term cardiac mortality increased in men
with PON-1 gene mutations
p4 | doi:10.1038/nrcardio.2009.217
http://links.ealert.nature.com/ctt?kn=18&m=34505386&r=MTc2NDI1MzEzNAS2&b=2&j=NjI4MDYxMzgS1&mt=1&rt=0
Atrial fibrillation: Is tecarfarin a better anticoagulant than warfarin?
p4 | doi:10.1038/nrcardio.2009.218
http://links.ealert.nature.com/ctt?kn=26&m=34505386&r=MTc2NDI1MzEzNAS2&b=2&j=NjI4MDYxMzgS1&mt=1&rt=0
----------------------
NEWS AND VIEWS
----------------------
Atrial fibrillation: Dronedarone and amiodarone-the safety versus
efficacy debate
Eric N. Prystowsky
p5 | doi:10.1038/nrcardio.2009.221
Amiodarone effectively maintains sinus rhythm in patients with atrial
fibrillation, and although dronedarone is less effective it has a better
safety profile. The choice of antiarrhythmic drug (or nonpharmacological
strategy) depends on the ultimate goal of therapy, which should be
considered in the context of the patient's clinical presentation and the
treatment tailored to the individual.
http://links.ealert.nature.com/ctt?kn=28&m=34505386&r=MTc2NDI1MzEzNAS2&b=2&j=NjI4MDYxMzgS1&mt=1&rt=0
Device therapy: Indications for ICD-CRT in mildly symptomatic heart failure
Johannes Holzmeister and William T. Abraham
p7 | doi:10.1038/nrcardio.2009.196
Clinical trial data, including those from MADIT-CRT, support the use of
cardiac resynchronization therapy in patients with asymptomatic and
mildly symptomatic heart failure and ventricular dyssynchrony. However,
important questions remain about which of these patients benefit most
from this therapy.
http://links.ealert.nature.com/ctt?kn=31&m=34505386&r=MTc2NDI1MzEzNAS2&b=2&j=NjI4MDYxMzgS1&mt=1&rt=0
Intervention: The AMADEUS study in perspective
Jason H. Rogers and Steven F. Bolling
p8 | doi:10.1038/nrcardio.2009.219
The Carillon system is a percutaneously delivered, coronary-sinus-based
mitral annuloplasty device. A safety and feasibility trial now
demonstrates low rates of major adverse events, with improvements in
quality of life. Though promising, this report raises important questions
related to relative efficacy and durability compared with other relevant
therapies, and related to current clinical indications.
http://links.ealert.nature.com/ctt?kn=42&m=34505386&r=MTc2NDI1MzEzNAS2&b=2&j=NjI4MDYxMzgS1&mt=1&rt=0
Atrial fibrillation: A promising new anticoagulant for stroke prevention
Sarah A. Spinler
p10 | doi:10.1038/nrcardio.2009.220
Stroke is the leading cause of morbidity and mortality in patients with
atrial fibrillation. Whereas warfarin reduces the risk of stroke, its
interactions with other drugs and food, individual differences in its
efficacy and the need for frequent monitoring make its use inconvenient.
Dabigatran etexilate might represent a step forward in the care of
patients with atrial fibrillation.
http://links.ealert.nature.com/ctt?kn=49&m=34505386&r=MTc2NDI1MzEzNAS2&b=2&j=NjI4MDYxMzgS1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
NEW from Nature Reviews Cardiology: Molecular Imaging Series
http://links.ealert.nature.com/ctt?kn=21&m=34505386&r=MTc2NDI1MzEzNAS2&b=2&j=NjI4MDYxMzgS1&mt=1&rt=0
Reviews and Perspective articles from leading specialists in cardiovascular
imaging.
The Molecular Imaging Series covers every aspect of the visualization
of physiological and pathophysiological processes at the cellular and
molecular levels.With each issue of Nature Reviews Cardiology until
spring 2010, a molecular-imaging-focused paper will be published in
print and added to our online article series.
=====================================================================
----------------------
REVIEWS
----------------------
Natriuretic peptides in heart failure: should therapy be guided by BNP
levels?
Michelle O'Donoghue and Eugene Braunwald
Published online: 24 November 2009
p13 | doi:10.1038/nrcardio.2009.197
The measurement of natriuretic peptides has emerged as an important tool
for the diagnosis and risk stratification of patients with heart failure,
but the use of these markers for monitoring treatment remains under
question. In this Review, Drs. O'Donoghue and Braunwald explore the
evolving role of natriuretic peptides in the guidance of heart failure
therapy and appraise data from clinical trials in this field.
Abstract: http://links.ealert.nature.com/ctt?kn=78&m=34505386&r=MTc2NDI1MzEzNAS2&b=2&j=NjI4MDYxMzgS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=53&m=34505386&r=MTc2NDI1MzEzNAS2&b=2&j=NjI4MDYxMzgS1&mt=1&rt=0
Cardiovascular effects of leptin
Gary Sweeney
Published online: 01 December 2009
p22 | doi:10.1038/nrcardio.2009.224
Leptin is thought to be intricately involved in pathophysiological
mechanisms linking obesity and cardiovascular disease. In this Review,
Dr. Sweeney highlights what is currently known about the cardiovascular
effects of leptin and discusses how these effects may explain the
so-called obesity paradox.
Abstract: http://links.ealert.nature.com/ctt?kn=29&m=34505386&r=MTc2NDI1MzEzNAS2&b=2&j=NjI4MDYxMzgS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=50&m=34505386&r=MTc2NDI1MzEzNAS2&b=2&j=NjI4MDYxMzgS1&mt=1&rt=0
Myocardial remodeling after infarction: the role of myofibroblasts
Susanne W. M. van den Borne, Javier Diez, W. Matthijs Blankesteijn,
Johan Verjans, Leo Hofstra and Jagat Narula
Published online: 01 December 2009
p30 | doi:10.1038/nrcardio.2009.199
In this Review, Dr. van den Borne and colleagues examine the role of
myofibroblasts in beneficial and adverse myocardial remodeling after
myocardial infarction. The authors also briefly discuss strategies for
imaging myofibroblasts, which might be useful for the early detection of
adverse remodeling events and for predicting the risk of heart failure.
Abstract: http://links.ealert.nature.com/ctt?kn=79&m=34505386&r=MTc2NDI1MzEzNAS2&b=2&j=NjI4MDYxMzgS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=63&m=34505386&r=MTc2NDI1MzEzNAS2&b=2&j=NjI4MDYxMzgS1&mt=1&rt=0
PET and SPECT in cardiovascular molecular imaging
Lawrence W. Dobrucki and Albert J. Sinusas
Published online: 24 November 2009
p38 | doi:10.1038/nrcardio.2009.201
Continuing our series of Reviews on Molecular Imaging, Drs. Dobrucki
and Sinusas discuss the applications of PET and single photon emission
CT (SPECT) for the evaluation of cardiovascular disease, including
myocardial metabolism, neurohumoral activity, atherosclerosis, ventricular
remodeling, and angiogenesis.
Abstract: http://links.ealert.nature.com/ctt?kn=75&m=34505386&r=MTc2NDI1MzEzNAS2&b=2&j=NjI4MDYxMzgS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=58&m=34505386&r=MTc2NDI1MzEzNAS2&b=2&j=NjI4MDYxMzgS1&mt=1&rt=0
Cardiovascular effects of relaxin: from basic science to clinical
therapy
Xiao-Jun Du, Ross A. D. Bathgate, Chrishan S. Samuel, Anthony M. Dart
and Roger J. Summers
Published online: 24 November 2009
p48 | doi:10.1038/nrcardio.2009.198
Over the past two decades, there has been rapid progress in our
understanding of the pleiotropic actions of relaxin in the cardiovascular
system. In this Review, Dr. Du and colleagues discuss basic knowledge
of relaxin signaling mechanisms, findings from experimental animal models
of cardiovascular diseases, and findings from clinical trials on relaxin.
Abstract: http://links.ealert.nature.com/ctt?kn=77&m=34505386&r=MTc2NDI1MzEzNAS2&b=2&j=NjI4MDYxMzgS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=65&m=34505386&r=MTc2NDI1MzEzNAS2&b=2&j=NjI4MDYxMzgS1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
Call for papers - Nature Communications
Nature Communications, an innovative new online science journal, launching
in Spring 2010, is now accepting submissions. The journal will provide a
unique forum for the rapid publication of high-quality Articles, from short
communications to more in-depth studies, covering all areas of the physical,
chemical and biological sciences.
Submit now at
http://links.ealert.nature.com/ctt?kn=19&m=34505386&r=MTc2NDI1MzEzNAS2&b=2&j=NjI4MDYxMzgS1&mt=1&rt=0
=====================================================================
You have been sent this Table of Contents Alert because you have opted
in to receive it. You can change or discontinue your e-mail alerts at
any time, by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=69&m=34505386&r=MTc2NDI1MzEzNAS2&b=2&j=NjI4MDYxMzgS1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2010 Nature Publishing Group
=====================================================================
